Search results for "Hodgkin"

showing 10 items of 180 documents

Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial

2007

Hodgkin diseasechemotherapy
researchProduct

Methodological Issues in the Baffling Relationship Between Hepatitis C Virus and Non Hodgkin’s Lymphomas

2003

The association between Hepatitis C Virus infection and B-cell Non-Hodgkin’s Lymphoma has been the matter of several studies: they showed disagreeing results with a marked regional variability. In this paper we present a review of the literature, highlighting methodological issues and main statistically critical aspects. Review suggests that studies were often not methodologically well approached. Moreover, we present main results from an original case-control study conducted in Italy, in an area of high endemicity of Hepatitis C Virus infection. In particular, we put attention in selection of a properly matching control group and in the role of age as a confounding variable.

Hodgkin sbusiness.industryHepatitis C virusMixed cryoglobulinemiaConfoundingmedicinemedicine.diseasemedicine.disease_causebusinessVirologyClinical psychologyLymphoma
researchProduct

Bone marrow biopsy in Hodgkin's lymphoma.

2004

In the study of patients with Hodgkin's lymphoma (HL) the evaluation of bone marrow biopsy (BMB) can be difficult. In this review we analyze the main diagnostic features and the clinical risk factors of BM involvement. Although the role of BMB is criticized by some authors, its value is irreplaceable in the staging of HL and in the diagnosis of primary medullary HL. The Ann Arbor staging committee criteria should be revised and updated in the light of the current immunohistochemical studies that give a fundamental help in the diagnostic process. A single BMB should be adequate for diagnosis in most instances. In cases of suspicious involvement a controlateral BMB could be performed.

Hodgkin's lymphoma.Diagnosis DifferentialPractice Guidelines as TopicHumansBone marrowbiopsyBone Marrow ExaminationHodgkin DiseaseImmunophenotypingEuropean journal of haematology
researchProduct

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

2011

Abstract We reported that the clinical efficacy of dendritic cell–based vaccination is strongly associated with immunologic responses in relapsed B-cell non-Hodgkin lymphoma (B-NHL) patients. We have now investigated whether postvaccination antibodies from responders recognize novel shared NHL-restricted antigens. Immunohistochemistry and flow cytometry showed that they cross-react with allogeneic B-NHLs at significantly higher levels than their matched prevaccination samples or nonresponders' antibodies. Western blot analysis of DOHH-2 lymphoma proteome revealed a sharp band migrating at approximately 100 to 110 kDa only with postvaccine repertoires from responders. Mass spectrometry ident…

ImmunologyMice SCIDBiochemistryAntibodiesFlow cytometryAntigen-Antibody ReactionsCohort StudiesHSP105MiceAntigenhemic and lymphatic diseasesCell Line TumormedicineAnimalsHumansSerologic TestsHSP110 Heat-Shock Proteinsmedicine.diagnostic_testbiologybusiness.industryLymphoma Non-HodgkinHSP105; non-Hodgkin lymphoma.Cell BiologyHematologyCell cyclemedicine.diseaseImmunohistochemistryLymphomaGranzyme BGene Expression Regulation Neoplasticnon-Hodgkin lymphoma.Spectrometry Mass Matrix-Assisted Laser Desorption-IonizationImmunologybiology.proteinImmunohistochemistryAntibodybusinessDiffuse large B-cell lymphoma
researchProduct

Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts.

2012

A disseminated model of non-Hodgkin's lymphoma with prevalent liver metastasis was generated by intraperitoneal (i.p.) injection of EBV(+) B lymphoblastoid SKW6.4 in nude-SCID mice. The survival of SKW6.4 xenografts (median survival = 27 days) was significantly improved when hyaluronan scaffolds embedded with mesenchimal stem cells (MSC) were implanted in the abdominal area 4 days after SKW6.4 injection (median survival = 39.5 days). Mice implanted with MSC showed a significant improvement of hepatic functionality in lymphoma xenografts, as demonstrated by measurement of serum ALT/AST levels. Co-culture of MSC with lymphoma cells enhanced the release of hepatocyte growth factor (HGF) by MSC…

Liver functionality. Lymphoma-bearing xenograftsPathologymedicine.medical_specialtyTime FactorsCell SurvivalMice NudeCell CommunicationMice SCIDMesenchymal Stem Cell Transplantationlymphoma.Mesenchymal stem cells; hepato-protective; lymphoma.Metastasischemistry.chemical_compoundMicehemic and lymphatic diseasesCell Line Tumorhepato-protectiveHyaluronic acidMedicineAnimalsHumansPharmacology (medical)Aspartate AminotransferasesHyaluronic AcidMesenchymal stem cellPharmacologyMesenchymal stem cells; Liver functionality. Lymphoma-bearing xenograftsTissue Scaffoldsbusiness.industryHepatocyte Growth FactorLymphoblastLymphoma Non-HodgkinMesenchymal stem cellLiver NeoplasmsAlanine TransaminaseMesenchymal Stem Cellsmedicine.diseaseXenograft Model Antitumor AssaysCoculture TechniquesLymphomaOncologychemistryLiverCell cultureHepatocyte growth factorStem cellbusinessBiomarkersmedicine.drugInvestigational new drugs
researchProduct

Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.

2016

The hepatitis C virus (HCV) infected patients are prone to develop bone marrow or various tissue infiltrates with monoclonal B cells, monoclonal B lymphocytosis or different types of B cell non-Hodgkin's lymphoma (BCNHL), of which the most common are splenic marginal zone BCNHL, diffuse large BCNHL and follicular lymphoma. The association between chronic HCV infection and non Hodgkin's lymphoma has been observed especially in areas with high prevalence of this viral infection. Outside the limitations of some studies that have been conducted, there are also geographic, environmental, and genetic factors that contribute to the epidemiological differences. Various microenvironmental signals, s…

Lymphoma B-CellFollicular lymphomaAntineoplastic AgentsVirus ReplicationAntiviral Agents03 medical and health sciences0302 clinical medicinemedicineHumansLymphoma FollicularB cellCell ProliferationHepatitisB-Lymphocytesbusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsGastroenterologyHematopoietic Stem Cell TransplantationMinireviewsGeneral MedicineHepatitis CLymphoma B-Cell Marginal ZoneHepatitis BHepatitis C Chronicmedicine.diseaseLymphomaNon-Hodgkin's lymphomaLiver Transplantationmedicine.anatomical_structure030220 oncology & carcinogenesisImmunology030211 gastroenterology & hepatologyRituximabLymphoma Large B-Cell DiffuseHepatitis C AntigensbusinessRituximabmedicine.drugWorld journal of gastroenterology
researchProduct

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

2015

We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protein (HSP)H1/105 in function of their aggressiveness. Here, we now clarify its role as a functional B-NHL target by testing the hypothesis that it promotes the stabilization of key lymphoma oncoproteins. HSPH1 silencing in 4 models of aggressive B-NHLs was paralleled by Bcl-6 and c-Myc downregulation. In vitro and in vivo analysis of HSPH1-silenced Namalwa cells showed that this effect was associated with a significant growth delay and the loss of tumorigenicity when 10(4) cells were injected into mice. Interestingly, we found that HSPH1 physically interacts with c-Myc and Bcl-6 in both Namalwa cells and pr…

Lymphoma B-CellXenograft Model Antitumor AssayDNA-Binding ProteinImmunologyDown-RegulationMice SCIDSettore MED/08 - Anatomia PatologicaBiologyBiochemistryHSP110 Heat-Shock ProteinProto-Oncogene Proteins c-mycMiceDownregulation and upregulationimmune system diseasesCell Line Tumorhemic and lymphatic diseasesHeat shock proteinGene Knockdown TechniquesmedicineAnimalsHumansGene silencingHSP110 Heat-Shock ProteinsAnimals; Cell Line Tumor; DNA-Binding Proteins; Down-Regulation; Gene Knockdown Techniques; HSP110 Heat-Shock Proteins; Humans; Lymphoma B-Cell; Mice; Mice SCID; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays; Biochemistry; Immunology; Medicine (all); Hematology; Cell BiologyAnimalMedicine (all)Cell BiologyHematologymedicine.diseaseXenograft Model Antitumor AssaysIn vitroLymphomaDNA-Binding ProteinsCell cultureGene Knockdown TechniquesGene Knockdown TechniqueImmunologyProto-Oncogene Proteins c-bcl-6Cancer researchB-Cell Non-Hodgkin LymphomaHumanBlood
researchProduct

Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci.

2015

Autoimmune conditions and immune system-related genetic variations are associated with risk of non-Hodgkin lymphoma (NHL). In a pooled analysis of 8,692 NHL cases and 9,260 controls from 14 studies (1988-2007) within the International Lymphoma Epidemiology Consortium, we evaluated the interaction between immune system genetic variants and autoimmune conditions in NHL risk. We evaluated the immunity-related single nucleotide polymorphisms rs1800629 (tumor necrosis factor gene (TNF) G308A), rs1800890 (interleukin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561 (HLA class II), and rs2647012 (HLA class II)) and categorized autoimmune conditions as prim…

LymphomaEpidemiologyOriginal Contributionstumor necrosis factorFollicular lymphomaNon-HodgkininteractionSingle-nucleotide polymorphismHuman leukocyte antigenmedicine.disease_causePolymorphism Single NucleotideAutoimmune DiseaseMedical and Health SciencesMathematical SciencesAutoimmunityAutoimmune DiseasesRare Diseasesimmune system diseasesHLA Antigenshuman leukocyte antigenhemic and lymphatic diseasesGenotypemedicineGeneticsHumans2.1 Biological and endogenous factorsPolymorphismAetiologyCancerbusiness.industryTumor Necrosis Factor-alphaLymphoma Non-HodgkinInflammatory and immune systemautoimmune conditionsOdds ratioSingle NucleotideHematologymedicine.diseaseAutoimmune conditions - risk of non-Hodgkin lymphoma (NHL)LymphomaInterleukin-10Case-Control StudiesImmunologyHIV/AIDSbusinessDiffuse large B-cell lymphomaenvironment
researchProduct

LDH uzticamība ne-Hodžkina limfomas ārstēšanas terapijas efektivitātēs izvērtēšanai

2022

Saikne starp laktātdehidrogenāzi un ne-Hodžkina limfomu ir pierādīta, taču laktātdehidrogenāzes loma ir palikusi tikai prognostiska. Šajā pētījumā mēs nolēmām izpētīt, vai laktāta dehidrogenāze varētu aizstāt radioloģiskus izmeklējumus, piemēram, datortomogrāfiju un pozitronu emisijas tomogrāfiju,lai izvērtētu ne-Hodžkina limfomas ārstēšanas efektivitāti. Tika veikts retrospektīvs kvantitatīvs pētījums. Tika atlasīti 39 pacienti no Paula Stradiņa Klīniskās universitātes slimnīcas. Tika analizēti pacienta laboratoriskie un radioloģiskie izmeklējumi, mēs analizējām datus, izmantojot SPSS. Pacientiem diagnozes noteikšanas brīdī bija visaugstākais LDH līmenis, un ārstēšanas laikā LDH līmenis sa…

LymphomaNon-Hodgkin LymphomaLactate dehydrogenasePET scanMedicīnaCancer
researchProduct

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …

MDD0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisIMPACTBONE-MARROWFEATURESCHILDRENlong-term follow-uplcsh:RC254-282ArticleDISEASECLASSIFICATIONChildhood Anaplastic Large Cell Lymphoma03 medical and health sciences0302 clinical medicineInternal medicineADOLESCENTSmedicineVINBLASTINEProgression-free survivalYoung adultPathologicalAnaplastic large-cell lymphomachildhoodScience & Technologybusiness.industryHazard ratioCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCLALCL; MDD; childhood; long-term follow-up030104 developmental biologyOncology030220 oncology & carcinogenesisMinimal Disseminated DiseaseNON-HODGKIN-LYMPHOMAbusinessLife Sciences & BiomedicineCancers
researchProduct